Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | ADSCaN trial: testing accelerated radiotherapy in NSCLC

Matthew Hatton • 30 Jan 2020
BTOG 2020
Lung Cancer Non-Small Cell Lung Cancer

Matthew Hatton, MSc, MBChB, MRCP, FRCP, FRCR, University of Sheffield, Sheffield, UK, discusses the aims of the ADSCaN trial (ISRCTN47674500) testing accelerated, dose-escalated, chemo-radiotherapy in NSCLC. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Matthew Hatton

2:41
NCRI Lung Cancer Study Group: clinical trials
Matthew Hatton • 29 Jan 2020
1:16
Analyzing the National Lung Cancer Audit (NLCA)
Matthew Hatton • 30 Jan 2020
2:31
Research priorities and trial platforms for lung cancer
Matthew Hatton • 25 Jan 2019
2:08
Radiotherapy research in lung cancer: immunotherapy combos, MR imaging, intensification of chemo-RT
Matthew Hatton • 25 Jan 2019

Related Videos

0:37
STABLE-MATES: sublobar resection vs SAbR in high-risk patients with stage I NSCLC
Clive Peedell • 18 Apr 2024
0:44
BTOG 2024: networking highlights and insights
Clive Peedell • 18 Apr 2024
0:49
Ongoing trials in thoracic radiotherapy: evaluating current role and significance
Thomas Newsom-Davis • 18 Apr 2024
4:20
Insights from BTOG 2024: advancements in TNM Staging, systematic staging, & immunotherapy strategies
Thomas Newsom-Davis • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals